Our Company

Scindy Pharmaceutical, founded in 2021, is a research and development enterprise focusing on innovations in the field of nanocarriers. Our primary objective is to drive both the basic research and the clinical applications of novel therapies. We place a special emphasis on RNA, leveraging our cutting-edge i-Core nanodelivery technology.

Our team is composed of individuals with a wealth of knowledge and experience in both academia and industry. Our strategy is to focus our efforts on infectious diseases and rare diseases by fast-tracking the clinical applications of advanced technologies for the unmet challenges of these diseases.

We have harnessed the unique capabilities of our leading i-Core Lipid Nanoparticle (LNP) platform to successfully launch innovative gene vector products based on LNPs. These products are specifically tailored for cell and gene therapies, reflecting our commitment to pushing the boundaries in this crucial area of healthcare.

載體技術(shù)驅(qū)動(dòng)的新療法市場

Non-viral vectors, exemplified by lipid nanoparticles, are pivotal technologies for the development of gene therapy drugs, including RNA. With the progressive advancement of new liver and extrahepatic targeted LNP technologies, we anticipate a rapid growth in the market for novel cell and gene therapy treatments.

自主創(chuàng)新LNP，突破

Our i-Core LNP platform, equipped with novel lipid materials and algorithms, has successfully developed extrahepatic targeted LNP delivery technology for the lungs and skin. This achievement was made possible through the use of an efficient NeoLNP? formula screening system, effectively addressing the challenge of delivering immune cells and stem cells efficiently.

穩(wěn)健創(chuàng)新的商業(yè)模式

We aim to harness the strengths of our leading platform technology to execute a differentiated pipeline layout and foster the clinical transformation of innovative technologies. Concurrently, in response to market demand, we are accelerating the conversion of technological achievements. We are developing new transfection vector products based on LNP technology, and we anticipate the launch of LNP vector products for immune cells (T/NK) and stem cells (MSC/iPSC) in the fourth quarter of 2023.

完備高效的核心團(tuán)隊(duì)

Our team boasts an exceptional academic and industrial background. The core team members have been deeply immersed in the field of drug research and development for decades, bringing a wealth of industry experience to the table. Our founder, who has been a key player in taking the company public, leads this team. We have established a professional team that oversees the entire process from R&D to production and commercialization. With an international talent pool and a well-structured organization, we are well-equipped to make significant strides in our field.

Our Story

August 2023

Launched our proprietary i-Core LNP platform and opened it to serve academic and industrial users.
April 2023

Suzhou R&D Center, spanning over 1000 square meters, became operational.
2023
December 2022

One of our key team members received the prestigious title of “Leading Technology Talents in Suzhou Industrial Park”.
October 2022

Recognised as a "Jiangsu Province Science and Technology-oriented Small and Medium Enterprise."
May 2022

Completed our angel round financing.
2022
October 2021

Established Scindy Pharmaceutical’s headquarters in BioBAY, Suzhou.
2021

Our Company

Our Story

Our Investors

Our Company

01

02

03

04

Our Story

August 2023

April 2023

December 2022

October 2022

May 2022

October 2021

Scindy Pharmaceutical (Suzhou) Co., Ltd.